IceCure Medical (ICCM) EBIT Margin (2020 - 2026)

IceCure Medical (ICCM) has 7 years of EBIT Margin data on file, last reported at 466.19% in Q1 2026.

• On a quarterly basis, EBIT Margin fell 3822.0% year-over-year to 466.19% in Q1 2026; TTM through Mar 2026 was 439.94%, a 3983.0% decrease from a year earlier, with the FY2025 full-year figure at 446.7%, down 3024.0% from the prior year.
• EBIT Margin for Q1 2026 stood at 466.19%, up from 329.63% in the prior quarter.
• Over the last five years, EBIT Margin for ICCM reached as high as 1260.86% in Q3 2023 and fell as low as 3146.54% in Q4 2022.
• Historically, EBIT Margin has averaged 180.49% across 5 years, with a median of 504.41% in 2025.
• Across the five-year window, EBIT Margin slumped 196735 bps in 2022 and soared 272726 bps in 2024, its largest moves.
• Year by year, EBIT Margin stood at 3146.54% in 2022, then grew by 30 bps to 2210.12% in 2023, then jumped by 123 bps to 517.14% in 2024, then tumbled by 36 bps to 329.63% in 2025, then jumped by 41 bps to 466.19% in 2026.
• Per Business Quant data, the three most recent EBIT Margin figures were 466.19% in Q1 2026, 329.63% in Q4 2025, and 451.29% in Q3 2025.